Semax Peptide

Please note: The FDA has not approved Semax for human use. The material presented on this page is for research and educational use only and is not medical advice, nor an endorsement of use outside a research setting.

Semax is a synthetic peptide, specifically a heptapeptide (a chain of seven amino acids: Met-Glu-His-Phe-Pro-Gly-Pro). It is a synthetic analog of a fragment of the adrenocorticotropic hormone (ACTH), designed to mimic its cognitive-enhancing (nootropic) and neuroprotective properties without having its hormonal effects.

Key Benefits

• May support cognitive function, focus, and mental clarity
• Commonly researched for neuroprotection and supporting brain recovery under stress
• May help enhance memory formation and learning capacity
• Research suggests potential benefits for mood regulation and stress resilience

Comprehensive Clinical and Pharmacological Guide to Semax

Prepared by Senior Pharmaceutical Content Division Peptide News Forum | Updated: September 13, 2026

Therapeutic Benefits of the Semax Peptide

Based on decades of Russian clinical research and emerging global studies, the compound has demonstrated a multifaceted therapeutic profile. While Western clinical validation remains limited, the documented benefits span neurological, cognitive, and neuroprotective domains.

Cognitive Enhancement and Nootropic Effects

• Enhanced Memory Consolidation: Clinical observations report improvements in both short-term and long-term memory formation, particularly in tasks requiring rapid information processing.
• Improved Learning Capacity: Users demonstrate accelerated acquisition of new skills and knowledge, attributed to BDNF-mediated synaptic plasticity.
• Heightened Focus and Attention: The compound modulates dopaminergic pathways in the prefrontal cortex, supporting sustained concentration and reduced distractibility.
• Mental Clarity: Many users report reduced brain fog and enhanced cognitive processing speed, particularly during periods of mental fatigue.

Neuroprotective Properties

• Ischemic Stroke Recovery: Russian clinical trials demonstrate reduced neurological deficits when administered within 6 hours of stroke onset, with improved functional outcomes compared to standard care.
• Neuronal Survival: The compound reduces oxidative stress and excitotoxicity, protecting neurons from ischemic and traumatic injury.
• Post-TBI Support: Emerging evidence suggests potential benefits in traumatic brain injury recovery through enhanced neuroplasticity and reduced secondary damage.
• Anti-Apoptotic Effects: Semax inhibits programmed cell death pathways in vulnerable neuronal populations.

Mood and Emotional Regulation

• Anxiolytic Effects: At lower doses (200-300 mcg), users report reduced anxiety without sedation, likely mediated by serotonergic modulation and enkephalinase inhibition.
• Stress Resilience: Animal studies demonstrate attenuated behavioral responses to chronic unpredictable stress, suggesting adaptive stress-response modulation.
• Mood Stabilization: Some clinical reports indicate antidepressant-like effects, though human data remains limited.
• Emotional Balance: Users frequently describe improved emotional regulation and reduced reactivity to stressors.

Neurorestorative and Regenerative Benefits

• BDNF Upregulation: The peptide significantly increases brain-derived neurotrophic factor expression in the hippocampus and cortex, promoting neurogenesis and synaptic remodeling.
• Neural Circuit Repair: Enhanced neurotrophic support facilitates recovery of damaged neural pathways following injury or disease.
• Angiogenesis: Research indicates promotion of new blood vessel formation in ischemic brain regions, supporting tissue recovery.
• White Matter Integrity: Preliminary data suggests potential benefits for myelination and white matter tract health.

Ophthalmic Applications

• Optic Nerve Protection: Russian clinical studies demonstrate stabilization or improvement of visual field parameters in glaucomatous optic neuropathy.
• Retinal Neuroprotection: The compound may protect retinal ganglion cells from degeneration through neurotrophic mechanisms.
• Visual Function Support: Patients with optic nerve diseases report preserved or enhanced visual acuity and contrast sensitivity.

Immunomodulatory and Vascular Effects

• Enhanced Immune Cell Activity: Transcriptomic studies reveal increased expression of immune-related genes and enhanced immune cell mobility.
• Anti-Inflammatory Action: The peptide modulates inflammatory cytokine profiles in ischemic conditions, potentially reducing neuroinflammation.
• Vasodilation: The compound promotes arterial vasodilation, improving cerebral blood flow in compromised regions.
• Endothelial Function: Semax supports endothelial cell health and migration, critical for vascular repair and angiogenesis.

Important Clinical Considerations: The majority of documented benefits derive from Russian clinical literature and preclinical studies. Independent Western validation through large-scale, randomized controlled trials remains limited. Response to the compound varies significantly between individuals. These benefits do not constitute medical advice, and the peptide should not replace evidence-based treatments for serious neurological or psychiatric conditions without physician supervision.

Regulatory Status and FDA-Approved Uses of Semax

Currently, Semax holds no FDA-approved indications in the United States. It remains an approved prescription medication in Russia and select Eastern European nations.

Regulatory Status (Updated September 2026)

• Historical Context: Previously classified under FDA Category 2.
• Recent Developments: On April 22, 2026, it was removed from Category 2 following a directive from the HHS Secretary. Consequently, standard 503A/503B pharmacy compounding regulations now apply.
• PCAC Review: The Pharmacy Compounding Advisory Committee (PCAC) conducted its scheduled review on July 24, 2026, at the FDA White Oak Campus, specifically evaluating the compound for cerebral ischemia, migraine, and trigeminal neuralgia.

Russian-Approved Indications (Not Valid in the USA)

• Acute ischemic stroke and recovery
• Optic nerve diseases (including glaucomatous optic neuropathy)
• Cognitive impairment and attention deficit
• Peptic ulcer disease (for gastrointestinal protection)

Global Off-Label Research Indications

• Nootropic and cognitive enhancement (focus, memory, learning)
• Anxiety and stress management (at lower doses)
• Proposed ADHD applications
• Neuroprotection post-traumatic brain injury (TBI) or ischemia
• Depression (limited data) and proposed use in Rett syndrome

Trade Names and Manufacturers of the Semax Peptide

Russian Pharmaceutical Brands (Prescription-only; unavailable in standard US pharmacies)

• Standard 0.1% Nasal Drops: Originally developed by the Institute of Molecular Genetics (IMG), Russian Academy of Sciences, Moscow.
• N-Acetyl Variant: An acetylated formulation designed for enhanced blood-brain barrier (BBB) penetration and extended biological activity.
• N-Acetyl Amidate (NASA): A further modified iteration offering the longest duration of action among the available variants.

US Availability

• Compounding Pharmacies: Following its April 2026 Category 2 removal, the compound is technically available via licensed 503A compounding pharmacies with a valid physician prescription. However, formal FDA rulemaking remains pending; practitioners must verify current legal status before dispensing.
• Grey-Market Vendors: Available through unregulated online channels; these products lack FDA verification, sterility testing, or quality assurance.
• Imported Russian Products: Occasionally sourced through informal channels, but these are not subject to FDA inspection or regulatory oversight.

Clinical Dosage Guidelines for Semax

Note: There is no FDA-approved US dosing protocol. The following reflects established Russian clinical practice and global off-label use.

Intranasal Administration (Most Common Route)

• Standard Clinical Dose: 300–600 mcg/day (typically administered as a 0.1% solution: 1–2 drops per nostril, 1–3 times daily).
• Nootropic/Cognitive Enhancement: 200–300 mcg/day.
• Neuroprotective Applications: 600–900 mcg/day (typically in a supervised clinical setting).

Subcutaneous Injection (Off-Label)

• Typical Dose: 50–300 mcg once daily, preferably in the morning.
• Therapeutic Range: 100–600 mcg/day, depending on the specific clinical indication.

Cycling Protocols

• Standard Cycle: 10–14 days of daily administration, followed by a 2–4 week washout period.
• Alternative Protocol: Some regimens utilize a 5-days-on / 2-days-off schedule.
• Rationale: Cycling is consistently recommended to prevent receptor downregulation and tolerance development.

Available Formulations

• Nasal spray (0.1% solution): Preferred for central nervous system (CNS) effects due to direct nose-to-brain delivery via the olfactory pathway.
• Lyophilized powder: For reconstitution (injectable).
• Transdermal formulations: Available but less extensively studied.

Cost and Pricing Dynamics of Semax Peptide

• Imported Russian Nasal Drops: Approximately $30–$60 per 3 mL bottle (0.1% solution). Estimated monthly cost: $30–$80, depending on dosage.
• Compounded Formulations (503A Pharmacy): Approximately $80–$200 per month, varying by pharmacy, specific formulation, and prescribed dose (where legally accessible with a prescription).
• Research Peptide Vendors (Unregulated): Approximately $30–$70 per vial or bottle. Caution: Quality, purity, and sterility are not guaranteed.
• N-Acetyl / NASA Variants: Typically command a 20–50% premium over standard formulations due to advanced synthesis and enhanced pharmacokinetic profiles.

Insurance Coverage Landscape for Semax

This compound is not covered by any major insurance provider in the United States, as it remains an unapproved drug. All access is strictly cash-pay.

• ACA Marketplace: Not covered
• Employer-Sponsored Insurance: Not covered
• Medicare Part D: Not covered
• Medicaid: Not covered
• TRICARE: Not covered

Future Outlook: Even if favorable PCAC review outcomes lead to a Category 1 classification, enabling broader 503A compounding access, insurance coverage for compounded peptides historically remains exceptionally rare.

Clinical Tips and Best Practices for Semax Peptide Use

1. Monitor Regulatory Outcomes: Following the July 24, 2026, PCAC review, stay informed on FDA evaluations regarding cerebral ischemia, migraine, and trigeminal neuralgia. A favorable outcome solidifies licensed 503A pharmacy access.
2. Prioritize Quality: If utilizing imported Russian nasal drops, be aware that quality and potency can vary significantly between batches. A compounded, pharmaceutical-grade product from a licensed 503A pharmacy is strongly preferred when legally accessible.
3. Neurotrophic Synergy: The compound upregulates Brain-Derived Neurotrophic Factor (BDNF)—the same neurotrophin targeted by many contemporary antidepressants and cognitive therapies.
4. Adhere to Cycling: Short-cycle protocols (10–14 days on, followed by a break) are consistently recommended in Russian clinical practice to maintain receptor sensitivity and avoid tolerance.
5. Timing of Administration: Administer in the morning for cognitive or focus-enhancing effects. Its mild stimulant nature may disrupt sleep architecture if taken late in the day.

Reported Side Effects and Safety Profile of Semax

Based on Russian clinical literature and global off-label reporting (independent Western long-term safety data remains very limited).

Mild and Commonly Reported

• Nasal irritation or transient discoloration of the nasal cavity with intranasal use (~10% incidence in Russian clinical data).
• Mild, transient headache (typically resolving within the first few days of use).
• Transient dizziness.
• Mild stimulant effects: Increased alertness and energy, which may cause insomnia if dosed late in the day.
• Increased anxiety: Reported by a subset of users, particularly at higher doses or in individuals with baseline anxiety disorders.

Less Common

• Elevated blood glucose levels in patients with pre-existing diabetes (noted in Russian clinical data).
• Irritability or mood fluctuations at supratherapeutic doses.
• Nasal dryness or epistaxis (nosebleeds) associated with intranasal administration.

Animal Study Signals

• Pro-oxidant effects observed at high doses in certain animal models; clinical significance for humans at standard therapeutic doses remains unclear.

Overall Safety Profile

• Decades of Russian clinical data report low systemic toxicity and no significant hormonal or endocrine disruption.
• No known dependence, addiction, or withdrawal syndrome.
• Key Published Concerns: Nasal discoloration (~10%) and elevated blood glucose in diabetic populations.

Disclaimer: Independent Western long-term safety data is sparse. The current safety profile relies heavily on historical Russian clinical experience.

Contraindications and Precautions for the Semax Peptide

No formal FDA contraindications exist due to the lack of an approved US label. The following are derived from Russian prescribing information and pharmacological properties:

• Hypersensitivity: Known allergy to the active ingredient or any of its excipients.
• Pregnancy and Breastfeeding: Insufficient safety data; use is not recommended.
• Pediatric Population: Limited data; safety and efficacy are not established in children.
• Psychosis or Acute Psychiatric Conditions: Dopaminergic and serotonergic modulation may exacerbate symptoms; use with extreme caution.
• Active Seizure Disorders: Theoretical concern regarding lowered seizure threshold; use with caution.
• Diabetes Mellitus: Due to reports of elevated blood glucose, patients must monitor blood sugar levels carefully.
• Drug Interactions: Combined use with Monoamine Oxidase Inhibitors (MAOIs) or strong serotonergic agents warrants caution due to theoretical interactions via serotonin pathway modulation.

Pharmacological Profile of Semax

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide (7 amino acids) derived from the adrenocorticotropic hormone (ACTH) fragment ACTH(4-10). Developed at the Institute of Molecular Genetics, Russian Academy of Sciences, it features an additional Pro-Gly-Pro sequence at the C-terminus. This modification significantly increases resistance to enzymatic degradation and extends biological activity compared to the native ACTH(4-10) fragment.

• Molecular Weight: Approximately 887 Daltons.
• Endocrine Activity: Crucially, the peptide lacks ACTH-like hormonal activity; it does not stimulate cortisol production or adrenal function. The parent ACTH(4-10) sequence retains CNS-active properties without the endocrine effects of full-length ACTH.
• Formulations: Available as a 0.1% nasal spray solution (exploiting the nasal-olfactory pathway for direct CNS delivery, bypassing first-pass systemic metabolism), lyophilized powder for injection, and specialized compounded formulations.

Mechanism of Action: How the Semax Peptide Works

The compound exerts its primary neurobiological effects through a multi-target mechanism involving neurotrophin and neurotransmitter pathways:

1. BDNF Upregulation (Primary Mechanism): It robustly stimulates the expression and release of Brain-Derived Neurotrophic Factor (BDNF) in the hippocampus and cortex. BDNF promotes neurogenesis, synaptic plasticity, and neural circuit repair, serving as the cornerstone of its cognitive and neuroprotective effects.
2. Serotonergic Modulation: It enhances serotonin metabolism in the striatum and hippocampus, contributing to mood stabilization, anxiety reduction (at low doses), and cognitive facilitation.
3. Dopaminergic Modulation: The peptide modulates dopaminergic activity in limbic regions, supporting motivation, attention, and reward processing.
4. Enkephalinase Inhibition: It inhibits enzymes responsible for breaking down endogenous enkephalins (opioid peptides), prolonging their activity and potentially contributing to analgesic and anxiolytic effects.
5. Neuroprotection: In ischemia and stroke models, it reduces oxidative stress, decreases neuronal apoptosis, and promotes functional recovery, a finding strongly supported by Russian clinical stroke data.
6. Nitric Oxide (NO) Modulation: Protective effects on cardiac tissue observed in animal myocardial infarction studies may be mediated through NO signaling pathways.

Clinical Claims and Research Outcomes for Semax

Russian Institute of Molecular Genetics / Russian Pharmaceutical Clinical Data

• Stroke Recovery: Russian clinical trials demonstrate reduced neurological deficits and improved functional outcomes when administered within 6 hours of ischemic stroke onset. Hospital-based trials also report improved cognitive recovery post-stroke compared to standard care controls.
• Glaucoma / Optic Nerve Disease: Research by Kurysheva et al. indicates that administration stabilized or improved visual field parameters in patients with optic nerve disease and glaucoma.
• Cognitive and ADHD Applications: Russian literature reports improvements in attention, memory consolidation, and learning speed. Furthermore, Tsai (2007) proposed the compound as a candidate therapeutic for ADHD and Rett syndrome, based on its robust BDNF-upregulating mechanism.

Alzheimer’s Drug Discovery Foundation (ADDF) Cognitive Vitality Report

• Noted “very little human evidence for potential side effects” based on published data.
• Acknowledged a favorable low-toxicity profile derived from Russian clinical experience.
• Conclusion: Concluded that current evidence is insufficient to recommend the compound for cognitive use in Western clinical practice without further rigorous, randomized controlled trial (RCT) data.

Critical Disclaimer: The vast majority of clinical evidence originates from Russian institutions. Independent Western clinical trials are exceedingly limited, and no Phase 3 data reviewed by the FDA currently exists for any indication.

Peptides to Similar to Semax

1. NAD+
2. MOTS-c
3. FOXO4-DRI
4. Epitalon
5. Pinealon
6. 5-Amino-1-MQ
7. Thymalin
8. Cerebrolysin
9. KPV
10. ARA-290

Disclaimer

This content about “Semax” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.